Revolution Medicines, Inc.
RVMDFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Revolution Medicines, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Revolution Medicines, Inc. — 10-K filed Feb 25, 2026
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 8 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 26, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 2026-03-31 | 3,338,142 | Not shown | SEC filing |
| Centiva Capital, LP | 2026-03-31 | 7,525 | Not shown | SEC filing |
| SCS Capital Management LLC | 2026-03-31 | 3,867 | Not shown | SEC filing |
| TWIN PEAKS WEALTH ADVISORS, LLC | 2026-03-31 | 15 | Not shown | SEC filing |
| Tredje AP-fonden | 2026-03-31 | 14,902 | Not shown | SEC filing |
| GAMMA Investing LLC | 2026-03-31 | 1,599 | Not shown | SEC filing |
| Vident Advisory, LLC | 2026-03-31 | 11,277 | Not shown | SEC filing |
| Allworth Financial LP | 2026-03-31 | 684 | Not shown | SEC filing |
| VAN ECK ASSOCIATES CORP | 2026-03-31 | 109,365 | Not shown | SEC filing |
| Bridgefront Capital, LLC | 2026-03-31 | 7,515 | Not shown | SEC filing |
| CenterBook Partners LP | 2026-03-31 | 5,769 | Not shown | SEC filing |
| TCG Crossover Management, LLC | 2026-03-31 | 576,473 | Not shown | SEC filing |
| UniSuper Management Pty Ltd | 2026-03-31 | 2,800 | Not shown | SEC filing |
| STRS OHIO | 2026-03-31 | 4,068 | Not shown | SEC filing |
| MassMutual Private Wealth & Trust, FSB | 2026-03-31 | 177 | Not shown | SEC filing |
| LORD, ABBETT & CO. LLC | 2026-03-31 | 134,233 | Not shown | SEC filing |
| Sanctuary Advisors, LLC | 2026-03-31 | 2,195 | Not shown | SEC filing |
| CIBC Asset Management Inc | 2026-03-31 | 8,276 | Not shown | SEC filing |
| ACUTA CAPITAL PARTNERS, LLC | 2026-03-31 | 26,069 | Not shown | SEC filing |
| Fieldview Capital Management, LLC | 2026-03-31 | 2,582 | Not shown | SEC filing |
- Each value is checked against Revolution Medicines, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 20 rows: the value per share could not be confirmed against the share prices on file from within three months of the report date.
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Revolution Medicines, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-06-17 · Horn Margaret A: Larger than 100 of the 107 other insider sales of Common Stock on file. SEC filing
- 2026-06-15 · Horn Margaret A: Larger than 106 of the 107 other insider sales of Common Stock on file. SEC filing
- 2026-04-15 · GOLDSMITH MARK A: Larger than all 107 other insider sales of Common Stock on file. SEC filing
- 2026-03-02 · GOLDSMITH MARK A: Larger than 97 of the 107 other insider sales of Common Stock on file. SEC filing
- 2026-01-07 · Horn Margaret A: Larger than 103 of the 107 other insider sales of Common Stock on file. SEC filing
- 2025-11-25 · GOLDSMITH MARK A: Larger than 105 of the 107 other insider sales of Common Stock on file. SEC filing
- 2025-11-07 · GOLDSMITH MARK A: Larger than 101 of the 107 other insider sales of Common Stock on file. SEC filing
- 2025-10-13 · Kelsey Stephen Michael: Larger than 99 of the 107 other insider sales of Common Stock on file. SEC filing
- 2025-09-15 · Kelsey Stephen Michael: Larger than 98 of the 107 other insider sales of Common Stock on file. SEC filing
- 2025-09-11 · Kelsey Stephen Michael: Larger than 104 of the 107 other insider sales of Common Stock on file. SEC filing
- 2025-09-11 · Kelsey Stephen Michael: Larger than 102 of the 107 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-24 | Anders Jack · Chief Financial Officer | Common Stock | S — Open market or private sale | −4,553 | 167.35 | SEC filing |
| 2026-06-24 | Anders Jack · Chief Financial Officer | Common Stock | S — Open market or private sale | −300 | 170.32 | SEC filing |
| 2026-06-24 | Anders Jack · Chief Financial Officer | Common Stock | S — Open market or private sale | −5,651 | 169.24 | SEC filing |
| 2026-06-24 | Anders Jack · Chief Financial Officer | Common Stock | S — Open market or private sale | −9,496 | 168.20 | SEC filing |
| 2026-06-17 | Horn Margaret A · Chief Operating Officer | Common Stock | S — Open market or private sale | −29,600 | 160.12 | SEC filing |
| 2026-06-16 | Anders Jack · Chief Financial Officer | Common Stock | S — Open market or private sale | −2,722 | 156.12 | SEC filing |
| 2026-06-16 | Mancini Anthony · See Remarks | Common Stock | S — Open market or private sale | −4,615 | 156.12 | SEC filing |
| 2026-06-16 | Cislini Jeff · General Counsel | Common Stock | S — Open market or private sale | −2,157 | 156.12 | SEC filing |
Showing 8 of 12 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-24 | Anders Jack · Chief Financial Officer | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | +20,000 | SEC filing |
| 2026-06-24 | Anders Jack · Chief Financial Officer | Common Stock | M — Exercise or conversion of derivative security | +20,000 | SEC filing |
| 2026-06-18 | Borellini Flavia · Director | Common Stock | A — Grant, award, or other acquisition | +1,191 | SEC filing |
| 2026-06-18 | Kim Lorence H. · Director | Common Stock | A — Grant, award, or other acquisition | +1,191 | SEC filing |
| 2026-06-18 | Kim Lorence H. · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +3,127 | SEC filing |
| 2026-06-18 | Borisy Alexis · Director | Common Stock | A — Grant, award, or other acquisition | +1,191 | SEC filing |
| 2026-06-18 | Patel Sushil · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +3,127 | SEC filing |
| 2026-06-18 | Patel Sushil · Director | Common Stock | A — Grant, award, or other acquisition | +1,191 | SEC filing |
Showing 8 of 25 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.